Introduction
============

The incidence of disease caused by *Mycobacterium tuberculosis* (MTB) infection in the UK has increased over the past 20 years and there were 8483 notifications of tuberculosis (TB) in 2010.[@b1] Co-infection with HIV was found in 4.9% of UK active TB cases in 2010,[@b1] and the total number of co-infection cases has increased year on year in the European region, from 9200 in 2007 to 13 821 in 2009.[@b2] The prevention of co-infection cases rests in part on treating latent tuberculosis infection (LTBI); however, there is little empiric evidence guiding LTBI screening in the HIV-positive population.

Treatment of LTBI reduces the risk of progression to active TB,[@b3] which in the setting of HIV co-infection is more severe and associated with extrapulmonary disease[@b4; @b5; @b6] and reduces the risk of onward transmission and infection.[@b7] The complex pharmacological interactions, risk of immune reconstitution inflammatory syndrome and considerable pill burden consequent upon treating both infections contemporaneously are thus avoided. Preventing active TB has potential cost savings; active TB treatment costs £7095.08 more than 6 months of isoniazid therapy.[@b8]

It is unknown whether the criteria for LTBI screening should be the same as in the general population or whether they should be tailored to the needs of the HIV-infected. Recently published National Institute for Health and Clinical Excellence (NICE) guidance[@b9] recommends that testing should be carried out in all contacts of active TB and new entrants from high incidence countries for the general population and the use of single- or dual-step screening based on CD4 count for the immunosuppressed. We postulated that the target HIV-infected population for LTBI screening should be broader because of the wealth of data demonstrating the resurgence of TB due to the HIV epidemic.[@b10] [@b11] HIV is the single most important risk factor for progression of LTBI to active disease and the risk of active TB increases with immunosuppression[@b12] [@b13] and is associated with MTB infection and re-infection.[@b14] Therefore, an effective screening strategy to detect and treat LTBI in those most likely to become infected and to progress to active disease is of public health interest.

Concerns regarding the sensitivity of both the tuberculin skin test (TST) and interferon-γ (IFN-γ) release assays (IGRAs) in the HIV-infected population have hindered their widespread use in HIV co-infection. The TST has poor sensitivity in HIV-infected patients[@b15] and poor specificity in those who have been BCG vaccinated[@b16] or those with a non-tuberculous mycobacterial infection. It is a well-characterised assay, however, which can improve targeting of chemoprophylaxis to those most likely to benefit.[@b17] New HIV guidelines suggest using IGRAs rather than TST for LTBI screening,[@b18] and NICE recommends IGRAs, with or without TST, dependent on CD4 count.[@b9] IGRAs use the antigenic targets, ESAT-6 and CFP-10, which are absent from BCG, improving sensitivity and specificity for the diagnosis of MTB infection.[@b16] [@b19] There is some evidence that the ELISpot platform is more sensitive in the setting of HIV than the TST,[@b19] [@b20] but more data are needed.

Current clinical practice for LTBI screening in the HIV population is not uniform. Some units, as exemplified by the two large HIV clinics studied, screen a broader target population for LTBI than the NICE criteria because of the increased risk of active TB. Since this approach is not based on empiric evidence, we examined the yield and case detection rate of LTBI cases using both the criteria recommended by NICE and by our broader research study criteria. To our knowledge, this is the first work to specifically address the effectiveness of the NICE criteria in the HIV-positive population.

Methods
=======

Subjects with HIV infection were prescreened by notes review for LTBI risk factors and recruited from two London HIV clinics (Imperial College Healthcare NHS Trust and Northwest London Hospitals NHS Trust) during January 2008--December 2010 as part of ongoing studies into HIV and MTB co-infection. Radiological findings, TST results and demographic data were collected. A cut-off of ≥5 mm was used for TST positivity.[@b17] [@b21] Patients with clinical (cough, fever, night sweats, haemoptysis, weight loss), radiological or microbiological evidence of active TB and those with a history of TB treatment or chemoprophylaxis were excluded. Data on risk factors for TB were systematically recorded as part of the parent study. A history of TB contact at any time (recent or remote) was recorded.

[Box 1](#box1){ref-type="boxed-text"} summarises current UK guidance for LTBI screening in HIV.

###### UK guidance for latent tuberculosis infection (LTBI) screening with reference to HIV co-infection

National Institute for Health and Clinical Excellence guidance on LTBI diagnosis[@b9]

1\. Tuberculosis (TB) contacts

Offer Mantoux testing in line with the Green Book to diagnose latent TB in people who are:

-   household contacts (aged 5 years and older) of all people with active TB.

-   non-household contacts (other close contacts, eg, in workplaces and schools).

Consider interferon-γ testing for people whose Mantoux testing shows positive results or in people for whom Mantoux testing may be less reliable, eg, BCG-vaccinated people.

If Mantoux testing is inconclusive, refer the person to a TB specialist.

2\. New entrants from high-incidence countries

Offer either an interferon-γ test alone or a dual strategy in people aged 16--35 years. For people aged 35 years or older, consider the individual risks and benefits of likely subsequent treatment, before offering testing.

3\. Immunocompromised

For people with HIV and CD4 counts less than 200 cells/μl, offer an interferon-γ test and a concurrent Mantoux test. If either test is positive: perform a clinical assessment to exclude active TB and consider treating latent TB infection.

For people with HIV and CD4 counts of 200--500 cells/μl, offer an interferon-γ test alone or an interferon-γ test with a concurrent Mantoux test. If either test is positive: perform a clinical assessment to exclude active TB and consider treating latent TB infection.

BHIVA 2011 guidelines[@b18]

Consider country of origin, CD4 count and length of time on highly active antiretroviral therapy. Close contacts of infectious TB should be offered chemoprophylaxis. Interferon-γ release assays rather than tuberculin skin test are recommended, although there is a call for more data.

UK guidance (NICE guidelines)
-----------------------------

NICE recommends screening TB contacts and new entrants (≤5 years) from high TB incidence countries (estimated incidence rate of 40/100 000)[@b9] in those aged 16--35 years and to consider the risks and benefits of treatment before offering testing to those aged 35 years or older. People with HIV who are in close contact with people with sputum smear-positive respiratory TB should have active disease excluded and then be given treatment for latent TB infection. Treatment of LTBI should be for people of any age who have HIV; therefore, an upper age limit for LTBI screening was not imposed in this study. Screening for immunosuppressed is recommended as a dual step (IGRA and TST) for those with a CD4 count \<200 cells/μl and as single or dual step for those with a CD4 count 200--500 cells/μl.

Research study screening approach
---------------------------------

HIV-positive participants were classified as at risk of LTBI according to a set of TB risk criteria. Those included had a history of TB contact and/or were migrants from a TB endemic country, regardless of date of entry into the UK or had two or more additional risk factors (see [table 1](#tbl1){ref-type="table"} for empirical evidence on TB risk factors): travel to a TB endemic area, smoking, more than occasional alcohol intake, homelessness, injecting drug use, prison stay or healthcare work.

###### 

Evidence for risk factors used in the study

  Risk factor                                                                                                                                                       Evidence
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Born in a TB endemic area                                                                                                                                         HR for TB recurrence for foreign born 3.2 (95% CI 1.2 to 9.0)[@b22]
  Adjusted OR for TST positivity for LTBI in students 43.5 (95% CI 25.2 to 72.3)[@b23]                                                                              
  Residence in a TB endemic area                                                                                                                                    OR for QFT positivity in HIV patients 5.7 (95% CI 2.6 to 12.5)[@b24]
  TB contact                                                                                                                                                        OR for QFT positivity in HIV patients 4.9 (95% CI 2.0 to 11.8)[@b24]
  OR for QFT positivity in HIV patients 7.8 (p=0.023)[@b25]                                                                                                         
  Alcohol                                                                                                                                                           HR for incident TB in men drinking 50--99 g alcohol per day 1.2 (95% CI 1.1 to 1.3) and ≥100 g alcohol per day 1.5 (95% CI 1.3 to 1.7)[@b26]
  Smoking                                                                                                                                                           HR for TB mortality in current male smokers 1.6 (95% CI 1.3 to 2.0) and incident TB current male smokers 1.4 (95% CI 1.3 to 1.5)[@b26]
  Smoking associated with TB (weighted OR 2.4, 95% CI 1.71 to 3.39, p\<0.001) and a worse clinical picture, e.g., cavitation (OR 1.76, 95% CI 1.18 to 2.63)[@b27]   
  Smoking associated with pulmonary TB (adjusted HR 2.87, 95% CI 2.00 to 4.11)[@b28]                                                                                
  Pulmonary TB associated with smoking aOR (1.5)[@b29]                                                                                                              
  Healthcare work                                                                                                                                                   TST conversion associated with nursing and ethnicity[@b30]
  TST conversion associated with place of healthcare work, e.g., infectious diseases HR 1.94 (95% CI 1.50 to 2.49) in multivariate analysis[@b31]                   
  Risk of TB higher for healthcare workers than the general population[@b32]                                                                                        
  Illicit drug use                                                                                                                                                  Higher rates of TST positivity in crack smokers[@b33]
  HR for TB recurrence 2.9 (95% CI 1.3 to 6.4)[@b22]                                                                                                                
  OR for QFT positivity in HIV patients 9.8 (p=0.031)[@b25]                                                                                                         
  Period of homelessness                                                                                                                                            OR for QFT positivity in HIV patients 5.2 (p=0.018)[@b25]
  Prison                                                                                                                                                            High prevalence of active TB in prisons in sub-Saharan Africa[@b34]
  Incidence rate ratio for LTBI 26.4 (IQR 13.0--61.8) and TB 23.0 (IQR 11.7--36.1)[@b35]                                                                            
  Multiple risk factors                                                                                                                                             OR in HIV patients for one or more risk factors 7.2 (2.9--18.2)[@b24]

LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test; QFT, QuantiFERON TB test.

Diagnosis of LTBI
-----------------

All participants were screened with the research study IGRA, an in-house IFN-γ MTB ELISpot. Evidence of an immunological response (positive IFN-γ secretion) to TB was made using the MTB region of difference−1 (RD−1) antigens, ESAT-6 and CFP-10, which are present in the commercial T-Spot^®^.*TB* assay, and thus, the results generated were considered to be equivalent to those generated by the commercial assay. The test was performed using pools of overlapping 15-mer peptides, as described previously.[@b36] A positive response was defined as at least five spot-forming cells more than the negative control well and at least twice the negative control well. Where participants had been screened as part of routine clinical work, this result was also used to define cases of LTBI. The commercial IGRAs, T-Spot^®^.*TB* or QuantiFERON^®^-TB Gold---In Tube (QFT), were performed by the clinical diagnostic laboratory. TST data were available for 20 cases but TST was not routinely performed in accordance with BHIVA guidance. We defined LTBI as a positive response in any of the screening assays (IGRA or TST).

Statistical analysis was performed using SPSS® Statistics (IBM®) V.20 and Prism 5 GraphPad Software, Inc, (La Jolla, California, USA). A Fisher\'s exact test was used to compare proportions. Significance was assessed at the 5% and 1% level.

Results
=======

Research study screening approach
---------------------------------

A total of 114 HIV-positive individuals were identified as at risk of LTBI according to the study protocol. Median age was 39 years (IQR 31.0--44.0), 77 (67.5%) were from sub-Saharan Africa and 11 (9.6%) were from central and southern America ([table 2](#tbl2){ref-type="table"}). The median (IQR) CD4 count was 412 (310--628) cells/μl and 72 (63.2%) were prescribed highly active antiretroviral therapy (HAART) at time of recruitment, 64 (56.1%) were women and 50 (43.9%) were men. Seventeen of 114 (14.9%, 95% CI 8.3 to 21.5) participants were diagnosed with LTBI in total. Results of IGRA and TST are presented in [table 3](#tbl3){ref-type="table"}. The local LTBI screening protocol detected nine (52.9%, 95% CI 26.5 to 79.3) cases and one had a negative screen (TST and IGRA) in the clinic but a positive study IGRA. Seven individuals (41.2%, 95% CI 15.1 to 67.3) who had not been referred for clinical screening had a positive research study IGRA. Therefore, the research study approach increased the number of individuals diagnosed with LTBI compared with current clinical services, with an overall case detection rate of 14.9% ([table 4](#tbl4){ref-type="table"}).

###### 

Demographic characteristics of participants eligible for LTBI screening

  Demographic                                    N=114   \%
  ---------------------------------------------- ------- ------
  Age (years)                                            
   ≤25                                           12      10.5
   26--35                                        32      28.1
   36+                                           70      61.4
  Sex                                                    
   Female                                        64      56.1
   Male                                          50      43.9
  Origin                                                 
   Europe, North America, Caribbean, Australia   13      11.4
   Middle East, North Africa                     2       1.8
   Other Asia                                    8       7.0
   Indian Subcontinent                           3       2.6
   Sub-Saharan Africa                            77      67.5
   Central and Southern America                  11      9.6
  BCG vaccinated                                         
   Yes                                           87      76.3
   No                                            9       7.9
   Unknown                                       18      15.8
  TST (mm)                                               
   ≥5                                            6       5.3
   \<5                                           14      12.2
   Not done                                      94      82.5
  CD4 count                                              
   0--199                                        14      12.3
   200--500                                      60      52.6
   \>500                                         40      35.1
  Viral load                                             
   \<50                                          49      43.0
   50--1000                                      24      21.1
   \>1000                                        41      36.0
  HAART therapy                                          
   Yes                                           72      63.2
   No                                            42      36.8

HAART, highly active antiretroviral therapy; LTBI, latent tuberculosis infection; TST, tuberculin skin test.

###### 

IGRA (commercial or research assay) and TST results

                 Positive IGRA   Positive TST   Total positive in either or both tests
  -------------- --------------- -------------- ---------------------------------------------------
  IGRA only      10/94           NA             10/94 (10.6%)
  TST and IGRA   6/20            6/20           7/20[\*](#table-fn1){ref-type="table-fn"} (35.0%)

All participants underwent research IGRA screening, of the 20 participants who also underwent TST, discordance occurred in two cases (one was positive who had a negative IGRA result and one was negative who had positive IGRA result).

IGRA, interferon-γ release assay; NA, not applicable; TST, tuberculin skin test.

###### 

Case detection rates for latent tuberculosis infection (defined as positive TST and/or IGRA) for different screening strategies

  Screening approach        Number tested   Number positive   Case detection rate (%)   Proportion of latent TB infection identified (%)
  ------------------------- --------------- ----------------- ------------------------- --------------------------------------------------
  Study                     114             17                14.9                      100.0
  NICE general population   43              9                 20.9                      52.9
  NICE immunosuppressed     74              8                 10.8                      47.1

IGRA, interferon-γ release assay; NICE, National Institute for Health and Clinical Excellence; TST, tuberculin skin test.

NICE guidance approach
----------------------

A smaller proportion would have fulfilled NICE guidance criteria for the general population (recent migrant from a TB endemic area or TB contact). Screening according to NICE guidance would have meant that 43/114 (37.7%, 95% CI 28.6 to 46.8) would have been eligible for screening of whom, 9/43 (20.9%, 95% CI 8.3 to 33.5) would have been diagnosed with LTBI ([table 4](#tbl4){ref-type="table"}). The remaining 71 (62.3%, 95% CI 53.2 to 71.3) would not be screened according to NICE guidance and 8/17 (47.1%, 95% CI 20.6 to 73.5) with LTBI would remain undiagnosed. The detection rate was not significantly higher than with the research study approach (p=0.470), and the diagnostic yield was only 52.9% of all LTBI cases detected.

When examining the criteria specifically for immunosuppressed patients suggested by NICE, 14/114 (12.3%, 95% CI 6.2 to 18.3) had a CD4 count of \<200 cells/μl and would have been eligible for dual-step screening and 60/114 (52.6%, 95% CI 43.3 to 61.9) had a CD4 count of 200--500 cells/μl and would have been eligible for single- or dual-step screening. A remaining 40/114 (35.1%, 95% CI 26.1 to 43.4) had a CD4 count of greater than 500 cells/μl and would not have been recommended either approach. Of those with LTBI, none had a CD4 count of \<200 cells/μl, 8/17 (47.1%, 95% CI 21.6 to 73.5) had a CD4 count of 200--500 cells/μl and 9/17 (52.9%, 95% CI 26.5 to 79.3) had a CD4 count of \>500 cells/μl. Therefore, using this approach, fewer than half the LTBI cases would have been detected, and the detection rate would have fallen to 8/74 (10.8%, 95% CI 3.6 to 18.1), although this was not different from the study approach (p=0.512).

Risk factors for LTBI
---------------------

A full TB risk history was taken at the time of recruitment to the study. The TB risk factors used for selection of subjects were chosen based on the available evidence ([table 1](#tbl1){ref-type="table"}). On univariate analysis, more than occasional alcohol intake (p=0.008), injecting drug use (p=0.023) and two or more (p=0.011) or three or more TB risk factors (p=0.002) were associated with LTBI ([table 5](#tbl5){ref-type="table"}). A history of recent or remote TB contact or a history of immigration from a TB endemic area within 5 years was not associated with LTBI. Multivariate analysis was not performed as numbers were small. The presence of multiple, rather than specific, TB risk factors was therefore most strongly associated with LTBI in this cohort.

###### 

Comparison of risk factors for latent TB infection from those used in the study screening approach

  TB risk factor                 Diagnosed with latent TB infection   No latent TB infection   p^a^          
  ------------------------------ ------------------------------------ ------------------------ ------ ------ --------------------------------------------
  Born in a TB endemic country   15                                   88.2                     83     85.6   NS
  New entrant                    4                                    23.5                     13     13.4   NS
  TB contact                     5                                    29.4                     23     23.7   NS
  Travel to a TB endemic area    11                                   64.7                     45     46.4   NS
  Alcohol                        7                                    41.2                     12     12.4   0.008[\*](#table-fn2){ref-type="table-fn"}
  Smoking                        6                                    35.3                     22     22.7   NS
  Healthcare work                3                                    17.6                     8      8.2    NS
  Injecting drug use             3                                    17.6                     2      2.1    0.023[†](#table-fn3){ref-type="table-fn"}
  Period of homelessness         1                                    5.9                      4      4.1    NS
  Prison                         2                                    11.8                     3      3.1    NS
  ≥2 risk factors                17                                   100.0                    69     71.1   0.011[†](#table-fn3){ref-type="table-fn"}
  ≥3 risk factors                13                                   76.5                     34     35.1   0.002[\*](#table-fn2){ref-type="table-fn"}

^a^p Values are for Fisher\'s exact test for each risk factor to compare those with and without LTBI.

Significance at 1% level.

Significance at 5% level.

NS, not significant; TB, tuberculosis.

Discussion
==========

The study has demonstrated that using currently available tools, a structured approach to screening in the HIV-positive population detects LTBI in one in seven of those with TB risk factors. Screening according to NICE guidance using either general population guidance or that specifically suggested for immunosuppressed individuals would only have detected half or fewer of these LTBI cases. This is an important finding given that recently published BHIVA guidance also recommends screening stratified by CD4 count.

The case detection rate from the study approach was not significantly different from the rates generated by the NICE approach. The number needed-to-be screened increased, however, from 43 with NICE-specified risk factors for the general population to 114. Although this represents a 2.7-fold increase, which carries a cost implication, this would place a minimal additional strain on resources. However, if NICE screening stratified by CD4 count were adopted, a total of 74 cases would have been eligible for single- or dual-step screening. The estimated costs of each test are: TST (£16.14); T-Spot^®^.*TB* (£55) and QFT (£45)[@b8]. In this study, the estimated additional cost of screening those who did not fulfil NICE criteria for immunosuppressed individuals (n=40) would have been £2200 for T-Spot^®^.*TB* alone and £2845.60 for a dual TST and T-Spot^®^.*TB* screening strategy. These costs, in addition to the cost of chemoprophylaxis (estimated at £524.59, range £262.30--£1049.18 for 6 months Isoniazid[@b8]), are small compared with the cost of treating one case of active TB/HIV co-infection, where treatment of TB alone has been estimated at £7619.67 (range £3809.84--£15239.34).[@b8]

Recent work has suggested that a single-step IGRA approach is cost effective,[@b9] as is screening in the immigrant population.[@b37] In our study, TST was positive in one individual with a negative IGRA. The increased risk of both progression and expensive-to-treat extrapulmonary or invasive disease in the HIV population would therefore be expected to improve the incremental cost-effectiveness ratios and thus increase the cost-effectiveness of screening for LTBI. In other clinical HIV cohorts, where there is a higher proportion of sub-Saharan Africans (in whom the prevalence of LTBI is highest), screening would also be more cost effective. A full cost-effectiveness analysis is required to determine whether single- or dual-step testing would be most appropriate in this population.

Extrapolating the study results to the wider UK setting, in 2010, there were 23 714 black Africans older than 14 years accessing care for HIV in the UK.[@b38] If we assume 14.9% (95% CI 8.3 to 21.5) would have LTBI (3533.4 cases), then approximately half would be diagnosed according to the NICE criteria for either the general or immunosuppressed population and 1766.7 cases would remain undiagnosed. Estimates of those at risk of developing active TB vary and include data from the pre-HAART era; estimates of 5%--8% in 1 year have been suggested,[@b3] [@b39] which would mean 88.3--141.3 at risk of developing active TB in the subsequent 12 months. Clinical observation in the HAART era suggests that this estimate may be too high. Long-term observational data are required to quantify this and to add to the limited available evidence for the prognostic power of IGRAs.[@b40]

The presence of multiple risk factors, rather than particular risk factors, was most highly associated with LTBI in our cohort. Since all patients with LTBI had two or more risk factors, there is potential to reduce the numbers screened by 25%. Studies in HIV-infected populations have been carried out in Europe; in Spain,[@b41] Germany[@b42] and Denmark,[@b24] rates of IGRA positivity of 6.7%--9.3%, 18.9%--24% and 4.6%, respectively, were found. Brock *et al*[@b24] showed that previous TB diagnosis, history of exposure, long-term residence in a TB endemic country and the presence of one risk factor or more were associated with a positive QFN. Active TB was associated with black African ethnicity, low CD4 count and a shorter time on HAART in a UK study.[@b43]

The diagnostic ability of the different assay platforms has been previously studied.[@b19] [@b44; @b45; @b46] There is evidence to suggest that the ELISpot platform retains sensitivity in HIV-infected individuals,[@b44] [@b47; @b48; @b49] but there is no gold standard test for LTBI and all methods may be affected by HIV-induced immunosuppression. Despite this, the use of the ELISpot platform in our study detected a significant rate of undiagnosed LTBI.

A pragmatic approach to screening for LTBI in HIV co-infection is both necessary and possible. Screening recent immigrants from endemic countries and TB contacts would identify just over half of all cases and can be recommended only as a minimum. Screening by stratification of CD4 count would also only detect less than half the cases. Expanding the screening criteria to include multiple risk factors, which would, using currently available assays double the yield without altering the case detection rate, should be considered as an alternative strategy.
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